Advanced Therapeutics最新文献

Mimicking Biochemical Traits with a Synthetic Lipid Nanoparticles SARS-COV-2 Model (Adv. Therap. 6/2025) 利用合成脂质纳米颗粒模拟SARS-COV-2模型的生化特性（Adv. Therap. 6/2025）

IF 3.7 4区医学

Advanced Therapeutics Pub Date : 2025-06-18 DOI: 10.1002/adtp.202570013

Ignasia Handipta Mahardika, Hyun Park, Eunjin Huh, Changyoon Baek, Shin-Gyu Cho, Kwang-Hwan Jung, Junhong Min, Kwanwoo Shin

引用次数: 0

Issue Information (Adv. Therap. 6/2025) 发行信息（add . therapy . 6/2025）

IF 3.7 4区医学

Advanced Therapeutics Pub Date : 2025-06-18 DOI: 10.1002/adtp.202570014

引用次数: 0

Nanoparticles and Their Impact on Epigenetic Mechanisms: Insights and Implications 纳米颗粒及其对表观遗传机制的影响：见解和启示

IF 3.7 4区医学

Advanced Therapeutics Pub Date : 2025-05-24 DOI: 10.1002/adtp.202500006

Zakieh Sadat Hoseini, Zahra Rezaee, Atefe Derakhshani, Sai-Yang Zhang, Sahar SH Tehrani, Mohammad Taleb, Hossein Ghanbari

{"title":"Nanoparticles and Their Impact on Epigenetic Mechanisms: Insights and Implications","authors":"Zakieh Sadat Hoseini, Zahra Rezaee, Atefe Derakhshani, Sai-Yang Zhang, Sahar SH Tehrani, Mohammad Taleb, Hossein Ghanbari","doi":"10.1002/adtp.202500006","DOIUrl":"https://doi.org/10.1002/adtp.202500006","url":null,"abstract":"Nanoparticles have been investigated for extensive applications across scientific disciplines, including the medical field. Despite extensive research aimed at enhancing the understanding of their intracellular behavior and the potential genomic side effects of nanoparticles, scientists have paid relatively little attention to nanoparticle-induced epigenetic changes. This oversight is surprising given the critical role of epigenetic mechanisms in shaping cellular function and destiny. Epigenetic mechanisms include the procedures that modulate DNA or RNA and influence the production of proteins as well as the extent to which they are produced. Each cell type demonstrates unique epigenetic profiles. Epigenetic changes can disrupt normal cellular functions, potentially leading to devastating outcomes. Investigating how nanoparticles impact these epigenetic mechanisms provides valuable insights into their safe and effective use in medical applications. This review provides a detailed overview of how nanoparticles enter cells and the impact of nanoparticles on epigenetic mechanisms, focusing on current related studies on different types of cells.","PeriodicalId":7284,"journal":{"name":"Advanced Therapeutics","volume":"8 6","pages":""},"PeriodicalIF":3.7,"publicationDate":"2025-05-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144309183","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Issue Information (Adv. Therap. 5/2025)

IF 3.7 4区医学

Advanced Therapeutics Pub Date : 2025-05-14 DOI: 10.1002/adtp.202570012

引用次数: 0

Antibiotic–Polycationic Peptide Conjugation as an Effective Strategy to Overcome Daptomycin Resistance (Adv. Therap. 5/2025)

IF 3.7 4区医学

Advanced Therapeutics Pub Date : 2025-05-14 DOI: 10.1002/adtp.202570011

Sari Rasheed, Florian Umstätter, Eric Mühlberg, Barbro Beijer, Tobias Hertlein, Karel D. Klika, Christian Kleist, Julia Werner, Cornelius Domhan, Mara Bingel, Anna Müller, Marvin Rausch, Stefan Zimmermann, Knut Ohlsen, Uwe Haberkorn, Marcus Koch, Markus Bischoff, Tanja Schneider, Rolf Müller, Jennifer Herrmann, Walter Mier, Philipp Uhl

引用次数: 0

Therapeutic Targeting of Osteosarcoma and Lung Metastases in Preclinical Models Using a CD24 Antibody-Drug Conjugate 使用CD24抗体-药物偶联物治疗骨肉瘤和肺转移的临床前模型

IF 3.7 4区医学

Advanced Therapeutics Pub Date : 2025-05-14 DOI: 10.1002/adtp.202400423

Peng Guo, Yuxuan Li, Jing Huang, Liming Jin, Xing Liu, Dawei He, Marsha A. Moses

{"title":"Therapeutic Targeting of Osteosarcoma and Lung Metastases in Preclinical Models Using a CD24 Antibody-Drug Conjugate","authors":"Peng Guo, Yuxuan Li, Jing Huang, Liming Jin, Xing Liu, Dawei He, Marsha A. Moses","doi":"10.1002/adtp.202400423","DOIUrl":"https://doi.org/10.1002/adtp.202400423","url":null,"abstract":"Pulmonary metastases present a significant clinical challenge in the treatment of osteosarcoma (OS). The current therapeutic landscape for metastatic OS is limited by the lack of effective targeted therapies. Here, the development and preclinical evaluation of a novel CD24 antibody-drug conjugate (ADC) designed for the targeted ablation of primary OS tumors and pulmonary metastases are reported. An unbiased, quantitative screening of cancer-related cell surface markers on human OS cells identifies CD24 as a novel target for ADC therapy in OS, owing to its disease-specific overexpression and rapid antigen-mediated internalization. Based on these findings, a proof-of-concept ADC, comprising a humanized CD24 antibody conjugated with mertansine (CD24-DM1), was designed and constructed. CD24-DM1 demonstrated potent cytotoxicity against a panel of human OS cell lines while sparing normal human osteoblasts. In an orthotopic OS model, CD24-DM1 induced complete and durable tumor regression. Additionally, CD24-DM1 significantly delayed tumor growth in a lung-metastatic OS model, providing robust in vivo evidence of CD24 as a promising ADC target for OS therapy. In conclusion, CD24-DM1 exhibits a favorable therapeutic index for the treatment of metastatic OS in preclinical models, highlighting its potential as an effective targeted therapeutic option.","PeriodicalId":7284,"journal":{"name":"Advanced Therapeutics","volume":"8 6","pages":""},"PeriodicalIF":3.7,"publicationDate":"2025-05-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144308849","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Synthetic Mucus Biomaterials Synergize with Antibiofilm Agents to Combat Pseudomonas aeruginosa Biofilms 合成黏液生物材料与抗菌膜剂协同对抗铜绿假单胞菌生物膜

IF 3.7 4区医学

Advanced Therapeutics Pub Date : 2025-04-29 DOI: 10.1002/adtp.202400359

Sydney Yang, Allison Boboltz, Alexa Stern, Vaidehi Rathi, Gregg Duncan

{"title":"Synthetic Mucus Biomaterials Synergize with Antibiofilm Agents to Combat Pseudomonas aeruginosa Biofilms","authors":"Sydney Yang, Allison Boboltz, Alexa Stern, Vaidehi Rathi, Gregg Duncan","doi":"10.1002/adtp.202400359","DOIUrl":"https://doi.org/10.1002/adtp.202400359","url":null,"abstract":"Bacterial biofilms are often highly resistant to antimicrobials causing persistent infections which, when not effectively managed, can significantly worsen clinical outcomes. As such, alternatives to standard antibiotic therapies have been highly sought after to address difficult-to-treat biofilm-associated infections. A biomaterial-based approach using the innate functions of mucins is hypothesized to modulate bacterial surface attachment and virulence can provide a new therapeutic strategy against biofilms. Based on the testing in Pseudomonas aeruginosa biofilms, it is found that synthetic mucus biomaterials can inhibit biofilm formation and significantly reduce the thickness of mature biofilms. In addition, if synthetic mucus biomaterials can work synergistically with DNase and/or α-amylase for enhanced biofilm dispersal is evaluated. Combination treatment with these antibiofilm agents and synthetic mucus biomaterials resulted in up to 2 log reductions in the viability of mature P. aeruginosa biofilms. Overall, this work provides a new bio-inspired, combinatorial approach to address biofilms and antibiotic-resistant bacterial infections.","PeriodicalId":7284,"journal":{"name":"Advanced Therapeutics","volume":"8 5","pages":""},"PeriodicalIF":3.7,"publicationDate":"2025-04-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/adtp.202400359","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143944970","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Mimicking Biochemical Traits with a Synthetic Lipid Nanoparticles SARS-COV-2 Model 用合成脂质纳米颗粒模拟SARS-COV-2模型的生化特性

IF 3.7 4区医学

Advanced Therapeutics Pub Date : 2025-04-28 DOI: 10.1002/adtp.202400401

Ignasia Handipta Mahardika, Hyun Park, Eunjin Huh, Changyoon Baek, Shin-Gyu Cho, Kwang-Hwan Jung, Junhong Min, Kwanwoo Shin

{"title":"Mimicking Biochemical Traits with a Synthetic Lipid Nanoparticles SARS-COV-2 Model","authors":"Ignasia Handipta Mahardika, Hyun Park, Eunjin Huh, Changyoon Baek, Shin-Gyu Cho, Kwang-Hwan Jung, Junhong Min, Kwanwoo Shin","doi":"10.1002/adtp.202400401","DOIUrl":"https://doi.org/10.1002/adtp.202400401","url":null,"abstract":"The continuous evolution of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) during the global pandemic challenges diagnostic technologies, underscoring the urgent need for quick adaptation and innovation to improve accuracy and efficiency against new variants. The study introduces a synthetic Lipid Nanoparticles (LNPs) model of SARS-CoV-2, utilizing advancements in LNPs vaccine technology to mimic the virus's key biochemical and genetic traits. This liposomal model encapsulates the characteristic SARS-CoV-2 mRNA and nucleocapsid (N) proteins within LNPs and further conjugates with spike (S) protein derivatives on its outer membrane, closely replicating the virus's structure and inducing accurate antigen-antibody responses in diagnostic tests. Furthermore, validation using reverse transcription-quantitative polymerase chain reaction (RT-qPCR) with commercial SARS-CoV-2 reagents confirms its effectiveness in simulating viral RNA amplification. This establishes it as an efficient tool for assessing the diagnostic efficacy of newly marketed diagnostic products. This LNPs model represents a significant advancement in diagnostic development, offering potential for therapeutic and vaccine research while ensuring safety and scalability.","PeriodicalId":7284,"journal":{"name":"Advanced Therapeutics","volume":"8 6","pages":""},"PeriodicalIF":3.7,"publicationDate":"2025-04-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/adtp.202400401","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144309212","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Nanoparticles Combining Host-Directed Therapeutics and Antibiotics to Boost Bacterial Killing and Overall Survival of Zebrafish Embryos Infected with Mycobacterium Marinum (Adv. Therap. 4/2025) 结合宿主导向疗法和抗生素的纳米颗粒提高感染海洋分枝杆菌的斑马鱼胚胎的细菌杀伤和总体存活率（ad . therapp . 4/2025）

IF 3.7 4区医学

Advanced Therapeutics Pub Date : 2025-04-18 DOI: 10.1002/adtp.202570009

Gabriela Schäfer, Dongdong Bi, Federico Fenaroli, Andrew M. Thompson, Anno Saris, Matthias Barz

引用次数: 0

Issue Information (Adv. Therap. 4/2025) 发行信息（ad . therapy . 4/2025）

IF 3.7 4区医学

Advanced Therapeutics Pub Date : 2025-04-18 DOI: 10.1002/adtp.202570010

引用次数: 0